Kidswell Bio Corporation [4584.T]
TOKYO, Mar 30 (Pulse News Wire) – Kidswell Bio Corporation (4584.T) decided to restructure its research and development operations aimed at advancing cell therapy treatments based on stem cells derived from deciduous teeth pulp (SHED). The move targets enhancing efficiency and optimizing resource allocation towards key areas within its subsidiary, S-Quatre.
Since 2019, S-Quatre has spearheaded the development of SHED-based therapeutic drugs. In June 2023, clinical trials began at Nagoya University, focusing on cerebral palsy treatment using patient-specific SHED cells. By October 2025, safety evaluations confirmed no issues up to four weeks post-treatment, while interim analysis showed promising results indicating functional improvements up to 12 weeks later. Additionally, an agreement was reached with Holda Pharmaceutical Co., Ltd. in March 2025 to collaborate on practical applications targeting pediatric cerebral palsy, currently preparing for trial initiation. In November 2025, S-Quatre held a Pre-IND meeting with the FDA, leveraging insights from ongoing clinical studies. Based on discussions, preparations for initiating a cerebral palsy-focused clinical trial are underway.
Furthermore, in February 2026, Kidswell Bio entered into an agreement with British Treehill Partners to establish a joint venture in the United States, aiming to accelerate overseas clinical development. Recognizing significant progress toward SHED's practical application, Kidswell Bio has defined cerebral palsy as the top priority indication for cell therapy. Consequently, the company plans to concentrate resources strategically on this area. As part of this strategy, S-Quatre’s research functions and resources will be consolidated at the Sapporo Institute, intensifying research efforts. Meanwhile, the Tokyo Lab’s research capabilities will be integrated into the Sapporo Institute by the end of June 2026. Technological insights and research outcomes gained through previous work at the Tokyo Lab will continue to be valuable assets for future developments and business expansion within the group. Regarding the impact of these restructuring measures on the group's fiscal year ending March 2026, Kidswell Bio is currently conducting a detailed assessment.
Any further significant developments will be disclosed promptly.
🟢 Confidence: High AI-translated content.